Onkologie. 2018:12(2):78-81 | DOI: 10.36290/xon.2018.016

Neoadjuvant chemotherapy for advanced ovarian cancer

Jana Ďurková
Oddelenie rádioterapie a klinickej onkológie, FN Nitra, Slovenská republika

Epithelial cancers of ovarian, fallopian tube, and peritoneal origin exhibit similar clinical characteristics and behavior. As such, theseare often combined together and define epithelial ovarian cancer (EOC) in clinical trials and clinical. Nearly 75 % of women withovarian cancer are diagnosed with advanced stage disease at presentation. Treatment with primary cytoreductive surgery (PDS)followed by chemotherapy has been the standard of care for these women. The aim of this article is to set out the rationale for,and data supporting the use of, neoadjuvant chemotherapy (NACT), because therapeutic benefit of neoadjuvant chemotherapyfollowed by interval cytoreduction remains controversial.

Keywords: ovarian cancer, neoadjuvant chemotherapy, primary cytoreductive surgery, overal survival

Published: April 1, 2018  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Ďurková J. Neoadjuvant chemotherapy for advanced ovarian cancer. Onkologie. 2018;12(2):78-81. doi: 10.36290/xon.2018.016.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. American Cancer Society.Cancer facts & Figures 2017. [online]. Atlanta: American Cancer Society; 2017 [cit. 3-1-2018]. Dostupné z: https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2017/cancer-facts-and-figures-2017.pdf
    2. Jemal A, Siegel R, Xu JQ, et al. Cancer Statistics, 2010. Ca-A Cancer Journal for Clinicians 2010; 60(5): 277-300. Go to original source... Go to PubMed...
    3. Záveský L. CA125/MUC16 jako diagnostický a prognostický marker pro karcinom ovaria, Onkologie 2012; 6(2): 65-67.
    4. Fischerová D, Zikán M, Pinkavová I, et al. Předoperační diagnostika ovariálních nádorů, Onkologie 2012; 6(2): 59-64.
    5. Griffiths CT. Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. Natl Cancer Inst Monogr. 1975;42:101-4. Go to PubMed...
    6. Pilka R. Karcinom ovaria - slovo úvodem, Onkologie 2012; 6(2): 58.
    7. Bristow RE, Tamacrus RS, Armstrong DK, et al. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 2002; 20(5): 1248-1259. Go to original source... Go to PubMed...
    8. Mandard AM, Dalibard F, Mandard JC, et al. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations. Cancer. 1994 Jun 1; 73(11): 2680-6. Go to original source...
    9. Vergote I, Tropé CG, Amant F, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med. 2010; 363: 943. Go to original source... Go to PubMed...
    10. Ledermann JA, Raja FA, Fotopoulou C, et al. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Annals of Oncology 2013; 24 (Supplement 6): vi24-vi32. Go to original source... Go to PubMed...
    11. Kehoe S, Hook J, Nankivell M, et al. Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial. Lancet. 2015; 386: 249-57. Go to original source... Go to PubMed...
    12. Chi DS, Musa F, Dao F, et al. An analysis of patients with bulky advanced stage ovarian, tubal, and peritoneal carcinoma treated with primary debulking surgery (PDS) during an identical time period as the randomized EORTC-NCIC trial of PDS vs neoadjuvant chemotherapy (NACT). Gynecol Oncol. 2012; 124: 10-4. Go to original source... Go to PubMed...
    13. Mueller JJ, Zhou QC, Iasonos A, et al. Neoadjuvant chemotherapy and primary debulking surgery utilization for advanced-stage ovarian cancer at a comprehensive cancer center. Gynecol Oncol. 2016; 140: 436-42. Go to original source... Go to PubMed...
    14. Wright AA, Bohlke K, Armstrong DK, et al. Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2016; 34: 3460-73. Go to original source... Go to PubMed...
    15. Fagotti A, Scambia G. Counterpoint Primary Debulking Surgery vs Neoadjuvant Chemotherapy for Newly Diagnosed Advanced Ovarian Cancer.In cancernetwork.com [online]. [cit. 3-1-2018]. Dostupné z: http://www.cancernetwork.com/oncology-journal/counterpoint-primary-debulking-surgery-vs-neoadjuvant-chemotherapy-newly-diagnosed-advanced-ovarian
    16. Wright JD, Doan T, McBride R, et al. Variability in chemotherapy delivery for elderly women with advanced stage ovarian cancer and its impact on survival. Br J Cancer. 2008 Apr 8; 98(7): 1197-1203. Go to original source... Go to PubMed...

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.